http://www.pharmaasia.comPharmaAsia - Latest Updatesen-USCopyright 2012 Ten Alps Communications Asia. All rights reserved.Thu, 9 Feb 2012 18:55:07 +0800http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325Life Technologies announced that Ronnie Andrews, former CEO of Clarient and Segment Leader, GE Molecular Diagnostics, has joined the company as president, medical sciences.http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325Fri, 10 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325Life Technologies announced that Ronnie Andrews, former CEO of Clarient and Segment Leader, GE Molecular Diagnostics, has joined the company as president, medical sciences.http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325Fri, 10 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325Life Technologies announced that Ronnie Andrews, former CEO of Clarient and Segment Leader, GE Molecular Diagnostics, has joined the company as president, medical sciences.http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325Fri, 10 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/research-based-pharmaceutical-industry-pledges-14-billion-treatments-to-help-end-nine-neglected-tropical-diseases/9324The research-based pharmaceutical industry announced donations of 14 billion treatments this decade to support the elimination or control of nine key neglected tropical diseases (NTDs). Averaging 1.4 billion treatments annually, the donations build upon companies’ existing medicines donation programs which already reach millions of people around the world.http://www.pharmaasia.com/article/research-based-pharmaceutical-industry-pledges-14-billion-treatments-to-help-end-nine-neglected-tropical-diseases/9324Thu, 9 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/novozymes-biopharma-wins-technology-innovation-award/9323Novozymes Biopharma has received the 2012 Drug Delivery Partnerships (DDP) Technology Innovation award for the company’s half-life extension platform. The award recognizes the most exciting delivery technology of the year.http://www.pharmaasia.com/article/novozymes-biopharma-wins-technology-innovation-award/9323Wed, 8 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/novozymes-biopharma-wins-technology-innovation-award/9323Novozymes Biopharma has received the 2012 Drug Delivery Partnerships (DDP) Technology Innovation award for the company’s half-life extension platform. The award recognizes the most exciting delivery technology of the year.http://www.pharmaasia.com/article/novozymes-biopharma-wins-technology-innovation-award/9323Wed, 8 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/mabcure-signs-license-agreement-with-biotech-investment-corp/9322MabCure has signed a license agreement with Biotech Investment Corp. (Biotech), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15 percent of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5 percent on revenues.http://www.pharmaasia.com/article/mabcure-signs-license-agreement-with-biotech-investment-corp/9322Tue, 7 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/mabcure-signs-license-agreement-with-biotech-investment-corp/9322MabCure has signed a license agreement with Biotech Investment Corp. (Biotech), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15 percent of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5 percent on revenues.http://www.pharmaasia.com/article/mabcure-signs-license-agreement-with-biotech-investment-corp/9322Tue, 7 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/agilent-technologies-s-thought-leader-award-supports-chris-evelo-s-work-at-maastricht-university/9321Agilent Technologies the Agilent Technologies Foundation announced that Dr Chris Evelo and the department of bioinformatics at Maastricht University are the recipients of an Agilent Thought Leader Award supporting development of software to integrate different types of biological data. The goal of this award is to help accelerate breakthroughs in disease research by facilitating integrative systems biology approaches.http://www.pharmaasia.com/article/agilent-technologies-s-thought-leader-award-supports-chris-evelo-s-work-at-maastricht-university/9321Mon, 6 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/agilent-technologies-s-thought-leader-award-supports-chris-evelo-s-work-at-maastricht-university/9321Agilent Technologies the Agilent Technologies Foundation announced that Dr Chris Evelo and the department of bioinformatics at Maastricht University are the recipients of an Agilent Thought Leader Award supporting development of software to integrate different types of biological data. The goal of this award is to help accelerate breakthroughs in disease research by facilitating integrative systems biology approaches.http://www.pharmaasia.com/article/agilent-technologies-s-thought-leader-award-supports-chris-evelo-s-work-at-maastricht-university/9321Mon, 6 Feb 2012 00:00:00 +0800